External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jun 2017: Trial registered, NCT03197506
  2. 15 Jan 2018: Trial started, NCT03197506

The trials

NCT03197506: Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

State
Under way
Phase
Phase 2
People
52 taking part
Started
15 Jan 2018
Primary completion
16 Jul 2024
Arms
Group 2 (pembrolizumab, temozolomide, radiation therapy )
Results
Posted on the registry
  1. 23 Jun 2017: Trial registered
  2. 15 Jan 2018: Trial started
  3. 25 Mar 2026: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Incidence of Dose Limiting Toxicities

Primary outcome · Number of participants · 189 days

GroupAnalysedValue
Group 1 Dose Level 1 Cohort 131
Group 1 Dose Level 1 Cohort 231
Group 1 Dose Level 1 Cohort 330
Group 1 Dose Level 1 Cohort 431

Group 2 Overall Survival (OS) at 18 Months

Primary outcome · Number of participants · 18 months

GroupAnalysedValue
Group 23319

Incidence of Adverse Events

Secondary outcome · Number of participants · 14 months

GroupAnalysedValue
Group 1156
Group 23618

Time Until Treatment Related Grade 3+ Adverse Event

Secondary outcome · Median, Months · 14 months

GroupAnalysedValue
Group 115NA (95% Confidence Interval 3.7 to NA)
Group 2366.9 (95% Confidence Interval 4.7 to NA)

Time to Progression (Group 2)

Secondary outcome · Median, Months · 36 months

GroupAnalysedValue
Group 23610.7 (95% Confidence Interval 8.0 to 12.2)

Progression-free Survival (Group 2)

Secondary outcome · Median, Months · 36 months

GroupAnalysedValue
Group 23610.7 (95% Confidence Interval 8.0 to 12.2)

Time to Treatment Failure (Group 2)

Secondary outcome · Median, Months · 13 months

GroupAnalysedValue
Group 2368.3 (95% Confidence Interval 6.1 to 10.9)

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.